John Edward Robinson - 26 Dec 2025 Form 4 Insider Report for Cogent Biosciences, Inc. (COGT)

Reporting relationship: Chief Scientific Officer
Issuer ticker: COGT
Reported as of: 26 Dec 2025
Net transaction value: -$3,486,600
SEC form: 4
Accepted by SEC: 30 Dec 2025, 16:01:03 UTC
Prior SEC filing: 19 Dec 2025
Source filing: View source filing
Reporting owner signature: /s/ Evan D. Kearns, Attorney-in-Fact

Key filing fact

John Edward Robinson filed Form 4 for Cogent Biosciences, Inc. (COGT) on 30 Dec 2025.

Key facts

This page summarizes John Edward Robinson's Form 4 filing for Cogent Biosciences, Inc. (COGT).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 30 Dec 2025, 16:01.

Change

Previous filing in this sequence was filed on 19 Dec 2025.
Current net transaction value: -$3,486,600.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001856514 Primary reporting owner

Robinson John Edward

Relationship: Chief Scientific Officer
Address: C/O COGENT BIOSCIENCES, INC., 275 WYMAN STREET, 3RD FLOOR, WALTHAM
Signature: /s/ Evan D. Kearns, Attorney-in-Fact
Signature date: 30 Dec 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

COGT transaction

Common Stock

Sale

Transaction value: $3,486,600
Shares: -90,000
Change %: -39%
Price: $38.74
Shares after: 140,002
Date: 26 Dec 2025
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $38.51 to $39.01, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Footnote F2

Includes previously reported shares of common stock underlying restricted stock units granted to the Reporting Person, which are subject to certain vesting conditions.